NCT01946789 2025-01-22A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid TumorsAltor BioSciencePhase 1 Completed26 enrolled 22 charts
NCT03127098 2024-08-06QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing CancerNantCell, Inc.Phase 1/2 Terminated3 enrolled 6 charts